Catherine Mazzacco Takes A Bullish Stance, Acquiring Krystal Biotech Stock Options Worth $6K

A notable acquisition unfolded on June 30, as Mazzacco, Director at Krystal Biotech (NASDAQ:KRYS), reported the acquisition of stock options for 5,000 shares in an SEC filing.

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Mazzacco, Director at Krystal Biotech, acquired 5,000 stock options for KRYS with an exercise price of $137.46 per share.

Krystal Biotech shares are currently trading up by 0.9%, with a current price of $138.7 as of Tuesday morning. This brings the total value of Mazzacco's 5,000 shares to $6,199.

All You Need to Know About Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Breaking Down Krystal Biotech's Financial Performance

Revenue Growth: Krystal Biotech displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 94.88%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Insights into Profitability:

• Gross Margin: Achieving a high gross margin of 94.3%, the company performs well in terms of cost management and profitability within its sector.

• Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 1.24, Krystal Biotech showcases strong earnings per share.

Debt Management: Krystal Biotech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.

Financial Valuation:

• Price to Earnings (P/E) Ratio: The current P/E ratio of 32.96 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.

• Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 12.32 suggests overvaluation in the eyes of investors, considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 23.99, Krystal Biotech presents an attractive value opportunity.

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Exploring the Significance of Insider Trading

Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.

In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.

Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.

A Closer Look at Important Transaction Codes

Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Krystal Biotech's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.